<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592876</url>
  </required_header>
  <id_info>
    <org_study_id>SGN19A-003</org_study_id>
    <nct_id>NCT02592876</nct_id>
  </id_info>
  <brief_title>Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, open-label study is to evaluate the safety and efficacy of
      denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when
      compared to RICE alone in the treatment of patients with relapsed or refractory diffuse
      large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also
      be candidates for autologous stem cell transplant. Patients will be randomly assigned in a
      1:1 ratio to receive 3 cycles of study treatment with either denintuzumab mafodotin + RICE
      or RICE alone. The study will assess whether there is a difference between the 2 groups in
      the side effects that are reported and the number of patients who achieve complete remission
      at the end of their study treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Up to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving peripheral blood stem cell mobilization</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving autologous stem cell transplant</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphoma, B-cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, Follicular, Grade 3b</condition>
  <condition>Follicular Lymphoma, Grade 3b</condition>
  <arm_group>
    <arm_group_label>19A+RICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RICE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab, ifosfamide, carboplatin, and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denintuzumab mafodotin</intervention_name>
    <description>Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.</description>
    <arm_group_label>19A+RICE</arm_group_label>
    <other_name>SGN-CD19A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 by IV infusion, every 3 weeks for up to 3 cycles</description>
    <arm_group_label>19A+RICE</arm_group_label>
    <arm_group_label>RICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>5000 mg/m2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles</description>
    <arm_group_label>19A+RICE</arm_group_label>
    <arm_group_label>RICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 5 by IV infusion, every 3 weeks for up to 3 cycles</description>
    <arm_group_label>19A+RICE</arm_group_label>
    <arm_group_label>RICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>100 mg/m2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles</description>
    <arm_group_label>19A+RICE</arm_group_label>
    <arm_group_label>RICE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of CD20-positive relapsed or refractory diffuse
             large B-cell lymphoma (DLBCL; including de novo and transformed DLBCL) or Grade 3b
             follicular lymphoma

          -  Available representative tissue from the most recent biopsy after the last therapy;
             if such tissue is not available, a fresh biopsy must be obtained

          -  Received only frontline CD20-directed immunotherapy with anthracycline- or
             anthracenedione-based multi-agent chemotherapy. Monotherapy rituximab or other
             CD20-directed immunotherapy as maintenance therapy prior to frontline chemotherapy,
             and radiotherapy in a limited field or as part of the frontline treatment plan are
             permitted.

          -  Considered eligible for high-dose chemotherapy followed by autologous stem cell
             transplant (ASCT)

          -  Fluorodeoxyglucose (FDG)-avid disease by positive emission tomography (PET), and
             measurable disease greater than 1.5 cm in diameter

          -  Eastern Cooperative Oncology Group (ECOG) performance less than or equal to 2

          -  Adequate kidney and hematologic function assessed from baseline laboratory data

        Exclusion Criteria:

          -  Previous history of indolent lymphoma treated with more than 1 multi-agent
             chemotherapy regimen or previous cancer therapy for recurrent DLBCL or Grade 3b
             follicular lymphoma

          -  History of autologous or allogeneic stem cell transplant

          -  History of another primary invasive cancer, hematologic malignancy, or
             myelodysplastic syndrome that has not been in remission for at least 1 year

          -  History of progressive multifocal leukoencephalopathy (PML)

          -  Cerebral/meningeal disease related to the underlying malignancy that has not been
             definitively treated

          -  Known urinary tract obstruction

          -  Patients with the following ocular conditions: corneal disorders, monocular vision
             (i.e., best corrected visual acuity greater than or equal to 20/200 in one eye), or
             active ocular disorders requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Kostic, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chester Wicker</last_name>
      <phone>501-686-7000</phone>
      <email>WickerChesterA@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Pooja Motwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Ortega</last_name>
      <phone>626-218-0563</phone>
      <email>ricortega@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Mercy Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaunda Mcclung</last_name>
      <phone>619-713-7990</phone>
      <email>Mcclung.Shaunda@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Boyka Petrov</last_name>
      <phone>858-652-5496</phone>
      <email>petrov.boyka@scrippshealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marin Xavier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Cancer Center / University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Anderson</last_name>
      <phone>352-273-8296</phone>
      <email>adanderson@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Nam Dang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bijal Shah</last_name>
      <phone>813-745-8212</phone>
      <email>bijal.shah@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Bijal Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Cohen</last_name>
      <phone>404-778-1900</phone>
      <email>jonathon.cohen@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathon Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Pierchala</last_name>
      <phone>312-942-3327</phone>
      <email>linda_pierchala@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Sunita Nathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Riedell</last_name>
      <phone>773-702-8412</phone>
      <email>priedell@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Riedell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Fahey</last_name>
      <phone>708-327-3228</phone>
      <email>kfahey@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Joyce</last_name>
      <phone>617-667-9920</phone>
      <email>Rjoyce@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jacobsen</last_name>
      <phone>617-632-6633</phone>
      <email>eric_jacobsen@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Bachanova</last_name>
      <phone>612-625-5469</phone>
      <email>bach0173@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Veronika Bachanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Bartlett</last_name>
      <phone>314-362-5654</phone>
      <email>nbartlet@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Feldman</last_name>
      <phone>551-996-5234</phone>
      <email>Tatyana.Feldman@HackensackMeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Jacob</last_name>
      <phone>646-449-1304</phone>
      <email>jacoba@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan McCall</last_name>
      <phone>646-449-1125</phone>
      <email>mccalls@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Craig Moskowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Dittus</last_name>
      <phone>919-962-8565</phone>
      <email>chris_dittus@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Dittus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Bumgarner</last_name>
      <phone>704-403-2520</phone>
      <email>Kelly.Bumgarner@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Nilanjan Ghosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Shearin</last_name>
      <phone>919-668-2556</phone>
      <email>sherra.shearin@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Beaven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Pierre</last_name>
      <phone>214-648-7032</phone>
      <email>Desiree.Pierre@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Madhuri Vusirikala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souzanne Ouzounian</last_name>
      <phone>713-563-1429</phone>
      <email>souzouni@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Luis Fayad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Anderson</last_name>
      <phone>210-916-3338</phone>
      <email>sanderson@hjf.org</email>
    </contact>
    <investigator>
      <last_name>Russell Baur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Underwood</last_name>
      <phone>434-982-3947</phone>
      <email>KM3Q@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Douvas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seema Murthy Naslund</last_name>
      <phone>206-288-7303</phone>
      <email>murthys@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>United States</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishalee Kenkre</last_name>
      <phone>608-263-9823</phone>
      <email>vpkenkre@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Vaishalee Kenkre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin (Milwaukee)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Guhl</last_name>
      <phone>414-805-8746</phone>
      <email>jguhl@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Mehdi Hamadani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>October 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antigens, CD19</keyword>
  <keyword>Autologous Stem Cell Transplant</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma Grade 3b</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monomethylauristatin F</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Transformed Lymphoma / DLBCL</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Etoposide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
